Canada and the European Union are reportedly close to agreeing drugtesting standards, with Canada hoping for a deal in the next month or so.
Discussions have been underway for three years on the proposed mutual recognition agreement which covers pharmaceuticals, safety and certification standards for medical devices, telecommunications equipment and electrical equipment.
Roy Christianson, the EU spokesman in the Canadian capital of Ottawa, says only two issues are delaying a deal. One is getting agreement from Canada's provinces, as some certification procedures fall under their purview, and the other concerns a definition of rules of origin, as some products have Japanese or US components.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze